Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Biosynthesis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43925   clinical trials with a EudraCT protocol, of which   7306   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Biosynthesis. Displaying page 1 of 1.
    EudraCT Number: 2013-004269-15 Sponsor Protocol Number: D-13-01 Start Date*: 2014-03-17
    Sponsor Name:Insituto Aragonés de Ciencias de la Salud
    Full Title: Aspirin and colorectal cancer prevention. Exploring the platelet hypothesis of its mechanism of action
    Medical condition: We will perform this clinical study to address the hypothesis that low-dose aspirin given once daily is acting primarily by selectively acetylating platelet COX-1 and suppressing its activity throu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002885-30 Sponsor Protocol Number: ARES Start Date*: 2017-07-27
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Novel strategies of antithrombotic prophylaxis in patients with Essential Thrombocythemia (ET) at high risk of cardiovascular events: comparison of different dosing regimens of administration of l...
    Medical condition: Essential thrombocytemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000610-10 Sponsor Protocol Number: RivAsA Start Date*: 2020-01-27
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Effects of low-dose Rivaroxaban combined with low-dose Aspirin versus low-dose aspirin alone on in vivo platelet Activation, endothelial function and inflammation in type 2 diabetic patients with s...
    Medical condition: type 2 diabetic patients with stable peripheral or carotid artery disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10067825 Peripheral arterial disease LLT
    21.0 10027433 - Metabolism and nutrition disorders 10053247 Insulin-requiring type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002122-67 Sponsor Protocol Number: 1211 Start Date*: 2013-12-05
    Sponsor Name:EORTC
    Full Title: Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration.
    Medical condition: metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001789-39 Sponsor Protocol Number: LAVA1207-001 Start Date*: 2021-07-13
    Sponsor Name:LAVA Therapeutics N.V.
    Full Title: A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific γδ-T cel...
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002952-18 Sponsor Protocol Number: Protocol Start Date*: 2020-07-21
    Sponsor Name:Ashford and St Peter's Hospitals NHS Foundation Trust
    Full Title: Targeting de novo Pyrimidine Biosynthesis by leflunomide as a Novel Concept for the Treatment of Corona Virus Disease 2019 (COVID-19)
    Medical condition: Confirmed Covid-19 infection by RT-PCR
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-003575-11 Sponsor Protocol Number: VitaminD&TT Start Date*: 2013-03-05
    Sponsor Name:Medizinische Universität Graz, Innere Medizin
    Full Title: A randomized, double-blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on androgen levels in hypogonadal men
    Medical condition: Male hypogonadism (total testosterone <3ng/ml)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10000193 Male sex hormone abnormalities HLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021268-13 Sponsor Protocol Number: Letrozole2010-1 Start Date*: 2010-11-19
    Sponsor Name:University College Dublin
    Full Title: The Effects of Normalising Sex Hormone Levels in Obese Hypogonadal Men: A Prospective Randomized Comparator Controlled Parallel Arm Clinical Trial
    Medical condition: Obesity Related Male Hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029883 Obesity LLT
    12.1 10021011 Hypogonadism male LLT
    Population Age: Adults Gender: Male
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001488-40 Sponsor Protocol Number: CCFMS181/211 Start Date*: 2011-09-01
    Sponsor Name:FONDAZIONE MONZINO CENTRO CARDIOLOGICO
    Full Title: Antiplatelet effect of low doses of aspirin taken every 12 hours in patients undergoing coronary artery bypass graft and / or aortic valve replacement surgery with bioprostheses
    Medical condition: Coronary Atheroclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10003211 Arteriosclerosis coronary artery PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004157-33 Sponsor Protocol Number: CCM525 Start Date*: 2021-05-12
    Sponsor Name:CENTRO CARDIOLOGICO SPA FONDAZIONE MONZINO
    Full Title: Effect of the administration of 75 mg of acetylsalicylic acid + 200mg of triglycerides of n-3 series fatty acids (omega 3 + ASA) on the biosynthesis of platelet thromboxane A2 in patients with card...
    Medical condition: Chronic ischemic cardiopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10032060 Other forms of chronic ischemic heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001616-30 Sponsor Protocol Number: CORT125134-452 Start Date*: 2018-07-09
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome
    Medical condition: Endogenous Cushing Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) ES (Ongoing) BG (Ongoing) DE (Ongoing) IT (Ongoing) NL (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003720-32 Sponsor Protocol Number: SPECTRE2015 Start Date*: 2016-06-01
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: Combined Suppression Of Cholesterol Bioavailability And Androgen Deprivation Therapy To Treat Castration Resistant Prostate Cancer
    Medical condition: Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 15 22:27:37 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA